Norris A H, Reilly J P, Edelstein P H, Brennan P J, Schuster M G
Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, USA.
Clin Infect Dis. 1995 May;20(5):1137-44. doi: 10.1093/clinids/20.5.1137.
A retrospective study of patients who received chloramphenicol for the treatment of serious vancomycin-resistant enterococcal infections between 1 January 1993 and 31 August 1993 was conducted at the University of Pennsylvania Medical Center (Philadelphia). Antimicrobial susceptibilities as well as the clinical course of infection, adverse events, and response to therapy of 16 patients were reviewed. Forty-seven percent of enterococcal isolates were susceptible only to chloramphenicol, tetracycline, and nitrofurantoin. Types of infection included bacteremias (n = 7), abscesses (n = 7), and others (n = 5). Of 14 patients for whom a clinical response could be ascertained, eight (57%) showed improvement after treatment. Of 11 patients for whom a microbiological response could be ascertained, eight (73%) had sterile cultures after treatment. No lasting adverse effect related to the drug occurred. In-hospital mortality was 56%, but only one death could be directly attributed to vancomycin-resistant enterococcal infection. Chloramphenicol appears to be a useful and well-tolerated agent for the treatment of serious vancomycin-resistant enterococcal infections.
1993年1月1日至1993年8月31日期间，宾夕法尼亚大学医学中心（费城）对接受氯霉素治疗严重耐万古霉素肠球菌感染的患者进行了一项回顾性研究。回顾了16例患者的抗菌药敏情况以及感染的临床过程、不良事件和治疗反应。47%的肠球菌分离株仅对氯霉素、四环素和呋喃妥因敏感。感染类型包括菌血症（n = 7）、脓肿（n = 7）和其他（n = 5）。在14例可确定临床反应的患者中，8例（57%）治疗后病情改善。在11例可确定微生物学反应的患者中，8例（73%）治疗后培养结果无菌。未出现与该药物相关的持续性不良反应。住院死亡率为56%，但只有1例死亡可直接归因于耐万古霉素肠球菌感染。氯霉素似乎是治疗严重耐万古霉素肠球菌感染的一种有用且耐受性良好的药物。
